Versatile Biomimetic Nanomedicine for Treating Cancer and Inflammation Disease

Overview

Journal Med Rev (2021)

Publisher De Gruyter

Specialty General Medicine

Date 2023 Sep 19

PMID 37724085

Authors

Zhiwen Zhao

Dangge Wang

Yaping Li

Affiliations

Soon will be listed here.

Abstract

Nanosized drug delivery systems (NDDSs) have emerged as a powerful tool to optimize drug delivery in complex diseases, including cancer and inflammation. However, the therapeutic effect of NDDSs is still far from satisfactory due to their poor circulation time, low delivery efficiency, and innate toxicity. Fortunately, biomimetic approaches offer new opportunities to develop nanomedicine, which is derived from a variety of native biomolecules including cells, exosomes, bacteria, and so on. Since inheriting the superior biocompatibility and versatile functions of natural materials, biomimetic nanomedicine can mimic biological processes, prolong blood circulation, and lower immunogenicity, serving as a desired platform for precise drug delivery for treating cancer and inflammatory disease. In this review, we outline recent advances in biomimetic NDDSs, which consist of two concepts: biomimetic exterior camouflage and bioidentical molecule construction. We summarize engineering strategies that further functionalized current biomimetic NDDSs. A series of functional biomimetic NDDSs created by our group are introduced. We conclude with an outlook on remaining challenges and possible directions for biomimetic NDDSs. We hope that better technologies can be inspired and invented to advance drug delivery systems for cancer and inflammation therapy.

Citing Articles

Generation of Anti-Epidermal Growth Factor Receptor-2 (HER2) Immunoliposomes Using Microbial Transglutaminase (mTG)-Mediated Site-Specific Conjugated Antibodies.

Berot A, Maniti O, El Alaoui S, Granjon T, El Alaoui M ACS Pharmacol Transl Sci. 2024; 7(10):3034-3044.

PMID: 39416960 PMC: 11475288. DOI: 10.1021/acsptsci.4c00197.

The utilization of nanotechnology in the female reproductive system and related disorders.

Luo X, Jia K, Xing J, Yi J Heliyon. 2024; 10(3):e25477.

PMID: 38333849 PMC: 10850912. DOI: 10.1016/j.heliyon.2024.e25477.

References

Rao L, Xia S, Xu W, Tian R, Yu G, Gu C . Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc Natl Acad Sci U S A. 2020; 117(44):27141-27147. PMC: 7959535. DOI: 10.1073/pnas.2014352117. View

Hotamisligil G . Inflammation, metaflammation and immunometabolic disorders. Nature. 2017; 542(7640):177-185. DOI: 10.1038/nature21363. View

Xu C, Jiang Y, Han Y, Pu K, Zhang R . A Polymer Multicellular Nanoengager for Synergistic NIR-II Photothermal Immunotherapy. Adv Mater. 2021; 33(14):e2008061. DOI: 10.1002/adma.202008061. View

Zheng Y, Tang L, Mabardi L, Kumari S, Irvine D . Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors. ACS Nano. 2017; 11(3):3089-3100. PMC: 5647839. DOI: 10.1021/acsnano.7b00078. View

Ai X, Wang D, Honko A, Duan Y, Gavrish I, Fang R . Surface Glycan Modification of Cellular Nanosponges to Promote SARS-CoV-2 Inhibition. J Am Chem Soc. 2021; 143(42):17615-17621. DOI: 10.1021/jacs.1c07798. View

Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang J . Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Mol Ther. 2019; 28(2):536-547. PMC: 7001084. DOI: 10.1016/j.ymthe.2019.11.020. View

Zhai Y, Ran W, Su J, Lang T, Meng J, Wang G . Traceable Bioinspired Nanoparticle for the Treatment of Metastatic Breast Cancer via NIR-Trigged Intracellular Delivery of Methylene Blue and Cisplatin. Adv Mater. 2018; :e1802378. DOI: 10.1002/adma.201802378. View

Doshi N, Swiston A, Gilbert J, Alcaraz M, Cohen R, Rubner M . Cell-based drug delivery devices using phagocytosis-resistant backpacks. Adv Mater. 2011; 23(12):H105-9. DOI: 10.1002/adma.201004074. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

10.

Deng G, Sun Z, Li S, Peng X, Li W, Zhou L . Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth. ACS Nano. 2018; 12(12):12096-12108. DOI: 10.1021/acsnano.8b05292. View

11.

Yue Y, Xu J, Li Y, Cheng K, Feng Q, Ma X . Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria. Nat Biomed Eng. 2022; 6(7):898-909. DOI: 10.1038/s41551-022-00886-2. View

12.

Sletten E, Bertozzi C . Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. Angew Chem Int Ed Engl. 2009; 48(38):6974-98. PMC: 2864149. DOI: 10.1002/anie.200900942. View

13.

Li R, Ng T, Wang S, Prytyskach M, Rodell C, Mikula H . Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Nat Nanotechnol. 2021; 16(7):830-839. PMC: 8491539. DOI: 10.1038/s41565-021-00897-1. View

14.

Minasyan H . Phagocytosis and oxycytosis: two arms of human innate immunity. Immunol Res. 2018; 66(2):271-280. DOI: 10.1007/s12026-018-8988-5. View

15.

Zhao Z, Fang L, Xiao P, Sun X, Zhou L, Liu X . Walking Dead Tumor Cells for Targeted Drug Delivery Against Lung Metastasis of Triple-Negative Breast Cancer. Adv Mater. 2022; 34(33):e2205462. DOI: 10.1002/adma.202205462. View

16.

Zhao Z, Ukidve A, Gao Y, Kim J, Mitragotri S . Erythrocyte leveraged chemotherapy (ELeCt): Nanoparticle assembly on erythrocyte surface to combat lung metastasis. Sci Adv. 2019; 5(11):eaax9250. PMC: 6853768. DOI: 10.1126/sciadv.aax9250. View

17.

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

18.

Chai Z, Ran D, Lu L, Zhan C, Ruan H, Hu X . Ligand-Modified Cell Membrane Enables the Targeted Delivery of Drug Nanocrystals to Glioma. ACS Nano. 2019; 13(5):5591-5601. DOI: 10.1021/acsnano.9b00661. View

19.

Huang W, Zhang Q, Li W, Yuan M, Zhou J, Hua L . Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism. J Control Release. 2019; 317:1-22. DOI: 10.1016/j.jconrel.2019.11.017. View

20.

Liao Y, Zhang Y, Blum N, Lin J, Huang P . Biomimetic hybrid membrane-based nanoplatforms: synthesis, properties and biomedical applications. Nanoscale Horiz. 2020; 5(9):1293-1302. DOI: 10.1039/d0nh00267d. View